Clinical Edge Journal Scan

How is psoriasis related to coronary inflammation and atherosclerotic burden?


 

Key clinical point: Patients with psoriasis showed lower coronary inflammation and higher atherosclerotic burden than matched control participants.

Major finding: Compared with cardiovascular disease (CVD) risk factor-matched control participants, patients with psoriasis showed a lower perivascular fat attenuation index (−80.19 ± 7.48 vs −78.14 ± 7.81 Hounsfield unit; P less than .001), indicating lower coronary inflammation and a higher overall computed tomography-adapted Leaman score (5.86 vs 4.69; P = .030).

Study details: This was a retrospective, single-center study including 98 patients with psoriasis and 196 CVD risk factor-matched control participants.

Disclosures: No specific funding for the study was disclosed. Z Xu declared being an employee of Siemens Healthineers CT Collaboration. No other potential conflict of interests was declared.

Source: Bao W et al. Dermatology. 2021 Sep 15. doi: 10.1159/000518771 .

Recommended Reading

Study of biologics’ impact on psoriasis-to-PsA transition contradicts previous findings
MDedge Dermatology
Secukinumab hits mark against pediatric plaque psoriasis
MDedge Dermatology
Risankizumab shows excellent long-term PASI response in psoriasis under real-world conditions
MDedge Dermatology
Patient-reported outcome measures complement clinician-reported outcomes in psoriasis
MDedge Dermatology
Cal/BD foam gains ground among patients with plaque psoriasis
MDedge Dermatology
Smokers with periodontitis are at soaring risk for psoriasis
MDedge Dermatology
Guselkumab: A promising treatment option for moderate-to-severe plaque psoriasis
MDedge Dermatology
Occult blood in feces tied to increased risk for psoriasis
MDedge Dermatology
High body weight and previous biologic use counter real-life guselkumab efficacy against plaque psoriasis
MDedge Dermatology
Delineating factors behind frequent biologic switching in psoriasis
MDedge Dermatology